Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) – Pipeline Review, H2 2016’, provides in depth analysis on Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1)

The report reviews Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects

The report assesses Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

AB Science SA

Amgen Inc.

AstraZeneca Plc

BCI Pharma

Chroma Therapeutics Limited

CTI BioPharma Corp.

Deciphera Pharmaceuticals, LLC

Eli Lilly and Company

F. Hoffmann-La Roche Ltd.

Five Prime Therapeutics, Inc.

Ignyta, Inc.

Johnson & Johnson

Novartis AG

Pfizer Inc.

Plexxikon Inc.

SignalChem Lifesciences Corp

Transgene SA

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC

2.7.10.1) Overview 10

Therapeutics Development 11

Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC

2.7.10.1) - Products under Development by Stage of Development 11

Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC

2.7.10.1) - Products under Development by Therapy Area 12

Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC

2.7.10.1) - Products under Development by Indication 13

Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC

2.7.10.1) - Pipeline Products Glance 16

Late Stage Products 16

Early Stage Products 17

Unknown Stage Products 18

Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC

2.7.10.1) - Products under Development by Companies 19

Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC

2.7.10.1) - Products under Development by Universities/Institutes 28

Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC

2.7.10.1) - Therapeutics Assessment 30

Assessment by Monotherapy/Combination Products 30

Assessment by Mechanism of Action 31

Assessment by Route of Administration 33

Assessment by Molecule Type 35

Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC

2.7.10.1) - Companies Involved in Therapeutics Development 37

AB Science SA 37

Amgen Inc. 39

AstraZeneca Plc 40

BCI Pharma 41

Chroma Therapeutics Limited 42

CTI BioPharma Corp. 43

Deciphera Pharmaceuticals, LLC 44

Eli Lilly and Company 45

F. Hoffmann-La Roche Ltd. 46

Five Prime Therapeutics, Inc. 47

Ignyta, Inc. 48

Johnson & Johnson 49

Novartis AG 50

Pfizer Inc. 51

Plexxikon Inc. 52

SignalChem Lifesciences Corp 54

Transgene SA 55

Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC

2.7.10.1) - Drug Profiles 56

AMG-820 - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

BLZ-945 - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

cediranib maleate - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

DCC-3014 - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

Drug to Antagonize CSF1R for Malignant Ascites - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

emactuzumab - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

FPA-008 - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

JNJ-28312141 - Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

JNJ-40346527 - Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

LY-3022855 - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

masitinib - Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

pacritinib - Drug Profile 84

Product Description 84

Mechanism Of Action 84

R&D Progress 84

pazopanib hydrochloride - Drug Profile 95

Product Description 95

Mechanism Of Action 95

R&D Progress 95

pazopanib hydrochloride + pembrolizumab - Drug Profile 102

Product Description 102

Mechanism Of Action 102

R&D Progress 102

PD-0360324 - Drug Profile 103

Product Description 103

Mechanism Of Action 103

R&D Progress 103

pexidartinib - Drug Profile 104

Product Description 104

Mechanism Of Action 104

R&D Progress 104

PLX-73086 - Drug Profile 108

Product Description 108

Mechanism Of Action 108

R&D Progress 108

PLX-7486 - Drug Profile 109

Product Description 109

Mechanism Of Action 109

R&D Progress 109

RXDX-105 - Drug Profile 110

Product Description 110

Mechanism Of Action 110

R&D Progress 110

Small Molecule to Antagonize CSF1R for Oncology and Neuroinflammation - Drug Profile 112

Product Description 112

Mechanism Of Action 112

R&D Progress 112

Small Molecule to Antagonize FLT3 and CSF1R for AML and Inflammation - Drug Profile 113

Product Description 113

Mechanism Of Action 113

R&D Progress 113

Small Molecules to Antagonize CSF-1 Receptor for Oncology - Drug Profile 114

Product Description 114

Mechanism Of Action 114

R&D Progress 114

Small Molecules to Antagonize CSF-1R for Inflammation - Drug Profile 115

Product Description 115

Mechanism Of Action 115

R&D Progress 115

Small Molecules to Inhibit cFMS Kinase for Immunology and Oncology - Drug Profile 116

Product Description 116

Mechanism Of Action 116

R&D Progress 116

Small Molecules to Inhibit FMS for Rheumatoid Arthritis - Drug Profile 117

Product Description 117

Mechanism Of Action 117

R&D Progress 117

Small Molecules to Inhibit FMS Kinase for Central Nervous System, Gastrointestinal, Immunology and Respiratory Diseases - Drug Profile 118

Product Description 118

Mechanism Of Action 118

R&D Progress 118

sunitinib malate - Drug Profile 119

Product Description 119

Mechanism Of Action 119

R&D Progress 119

TG-3003 - Drug Profile 124

Product Description 124

Mechanism Of Action 124

R&D Progress 124

Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC

2.7.10.1) - Dormant Projects 125

Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC

2.7.10.1) - Discontinued Products 134

Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC

2.7.10.1) - Featured News & Press Releases 140

Jul 04, 2016: Review of the conditional marketing authorization application of masitinib in amyotrophic lateral sclerosis (ALS) will follow the standard timeline of the European Medicines Agency (EMA) 140

Jun 07, 2016: Long-Term Follow Up Data For Pacritinib Presented At 2016 ASCO Annual Meeting 140

Jun 06, 2016: AB Science announces that Rapporteurs appointed by the EMA have recommended the filing of masitinib in ALS for conditional marketing authorization 144

Jun 05, 2016: Ignyta Announces Interim Data from Phase 1 Clinical Trial of Investigational Precision Medicine RXDX-105 at ASCO 2016 145

May 30, 2016: AB Science will Present Phase 3 Data in Severe Systemic Mastocytosis at the International 21St Congress of the European Hematology Association 146

May 24, 2016: Ignyta Announces RXDX-105 Phase 1 Data Presentation at the 2016 ASCO Annual Meeting 147

May 19, 2016: CTI BioPharma Announces Presentations At The American Society Of Clinical Oncology Annual Meeting 148

May 12, 2016: Five Prime Therapeutics Advances FPA008 Into Phase 2 Dose Expansion in Patients with Pigmented Villonodular Synovitis 149

May 02, 2016: AB Science has submitted to EMA the marketing authorization application for Masitinib in the Treatment of Severe Systemic Mastocytosis 149

Apr 20, 2016: Preclinical Data Presented At AACR Indicate Pacritinib Potential To Eradicate Therapy-Resistant Leukemia Stem Cells Residing In Bone Marrow Microenvironment 150

Apr 20, 2016: Deciphera’s Highly-Selective Small Molecule CSF1R Immunokinase Inhibitor, DCC-3014, Demonstrates Potent Macrophage Checkpoint Inhibition as a Single Agent and In Combination with an Anti-PD1 Inhibitor 151

Apr 13, 2016: CTI BioPharma Announces Presentation on pacritinib at the American Association of Cancer Research Annual Meeting 151

Apr 11, 2016: Masitinib in Amyotrophic Lateral Sclerosis (ALS) 152

Apr 06, 2016: AB Science Will Host Live Webcast On Phase 3 Interim Analysis In ALS On 8 April 2016, 156

Apr 04, 2016: Ab Science Announces Positive Interim Results From Phase 3 Trial Of Masitinib In Amyotrophic Lateral Sclerosis 157

Appendix 159

Methodology 159

Coverage 159

Secondary Research 159

Primary Research 159

Expert Panel Validation 159

Contact Us 159

Disclaimer 160

List of Tables

List of Tables

Number of Products under Development for, H2 2016 11

Number of Products under Development by Therapy Area, H2 2016 12

Number of Products under Development by Indication, H2 2016 13

Comparative Analysis by Late Stage Development, H2 2016 16

Comparative Analysis by Early Stage Products, H2 2016 17

Comparative Analysis by Unknown Stage Development, H2 2016 18

Number of Products under Development by Companies, H2 2016 19

Products under Development by Companies, H2 2016 20

Products under Development by Companies, H2 2016 (Contd..1) 21

Products under Development by Companies, H2 2016 (Contd..2) 22

Products under Development by Companies, H2 2016 (Contd..3) 23

Products under Development by Companies, H2 2016 (Contd..4) 24

Products under Development by Companies, H2 2016 (Contd..5) 25

Products under Development by Companies, H2 2016 (Contd..6) 26

Products under Development by Companies, H2 2016 (Contd..7) 27

Number of Products under Investigation by Universities/Institutes, H2 2016 28

Products under Investigation by Universities/Institutes, H2 2016 29

Assessment by Monotherapy/Combination Products, H2 2016 30

Number of Products by Stage and Mechanism of Action, H2 2016 32

Number of Products by Stage and Route of Administration, H2 2016 34

Number of Products by Stage and Molecule Type, H2 2016 36

Pipeline by AB Science SA, H2 2016 37

Pipeline by Amgen Inc., H2 2016 39

Pipeline by AstraZeneca Plc, H2 2016 40

Pipeline by BCI Pharma, H2 2016 41

Pipeline by Chroma Therapeutics Limited, H2 2016 42

Pipeline by CTI BioPharma Corp., H2 2016 43

Pipeline by Deciphera Pharmaceuticals, LLC, H2 2016 44

Pipeline by Eli Lilly and Company, H2 2016 45

Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 46

Pipeline by Five Prime Therapeutics, Inc., H2 2016 47

Pipeline by Ignyta, Inc., H2 2016 48

Pipeline by Johnson & Johnson, H2 2016 49

Pipeline by Novartis AG, H2 2016 50

Pipeline by Pfizer Inc., H2 2016 51

Pipeline by Plexxikon Inc., H2 2016 52

Pipeline by SignalChem Lifesciences Corp, H2 2016 54

Pipeline by Transgene SA, H2 2016 55

Dormant Projects, H2 2016 125

Dormant Projects (Contd..1), H2 2016 126

Dormant Projects (Contd..2), H2 2016 127

Dormant Projects (Contd..3), H2 2016 128

Dormant Projects (Contd..4), H2 2016 129

Dormant Projects (Contd..5), H2 2016 130

Dormant Projects (Contd..6), H2 2016 131

Dormant Projects (Contd..7), H2 2016 132

Dormant Projects (Contd..8), H2 2016 133

Discontinued Products, H2 2016 134

Discontinued Products (Contd..1), H2 2016 135

Discontinued Products (Contd..2), H2 2016 136

Discontinued Products (Contd..3), H2 2016 137

Discontinued Products (Contd..4), H2 2016 138

Discontinued Products (Contd..5), H2 2016 139

List of Figures

List of Figures

Number of Products under Development for, H2 2016 11

Number of Products under Development by Therapy Area, H2 2016 12

Number of Products under Development by Top 10 Indication, H2 2016 13

Comparative Analysis by Late Stage Development, H2 2016 16

Comparative Analysis by Early Stage Products, H2 2016 17

Assessment by Monotherapy/Combination Products, H2 2016 30

Number of Products by Mechanism of Actions, H2 2016 31

Number of Products by Stage and Mechanism of Actions, H2 2016 31

Number of Products by Routes of Administration, H2 2016 33

Number of Products by Stage and Routes of Administration, H2 2016 33

Number of Products by Molecule Types, H2 2016 35

Number of Products by Stage and Molecule Type, H2 2016 35

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports